
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Brand Name | Status | Last Update |
|---|---|---|
| asparlas | Biologic Licensing Application | 2024-10-08 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| precursor cell lymphoblastic leukemia-lymphoma | — | D054198 | C91.0 |
Expiration | Code | ||
|---|---|---|---|
calaspargase pegol, Asparlas, Servier Pharmaceuticals LLC | |||
| 2101-02-01 | Orphan excl. | ||
Code | Description |
|---|---|
| J9118 | Injection, calaspargase pegol-mknl, 10 units |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Drug common name | Calaspargase pegol |
| INN | calaspargase pegol |
| Description | Calaspargase pegol, sold under the brand name Asparlas, is a medication for the treatment of acute lymphoblastic leukemia (ALL). It is approved in the United States as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients aged one month to 21 years.
|
| Classification | Enzyme |
| Drug class | enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | 941577-06-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108728 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14730 |
| UNII ID | T9FVH03HMZ (ChemIDplus, GSRS) |

